PEPG Quote, Financials, Valuation and Earnings

Edgewise Therapeutics has a net margin of -- compared to PepGen's net margin of --. PepGen's return on equity of -- beat Edgewise Therapeutics's return on equity of --.

PepGen has a consensus price target of $15.40, signalling upside risk potential of 450%. On the other hand Edgewise Therapeutics has an analysts' consensus of $49.43 which suggests that it could grow by 95.14%. Given that PepGen has higher upside potential than Edgewise Therapeutics, analysts believe PepGen is more attractive than Edgewise Therapeutics.

PepGen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Edgewise Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

PepGen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen pays -- of its earnings as a dividend. Edgewise Therapeutics pays out -- of its earnings as a dividend.

PepGen quarterly revenues are --, which are smaller than Edgewise Therapeutics quarterly revenues of --. PepGen's net income of -$21.4M is higher than Edgewise Therapeutics's net income of -$34.1M. Notably, PepGen's price-to-earnings ratio is -- while Edgewise Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen is -- versus -- for Edgewise Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Regenxbio has a net margin of -- compared to PepGen's net margin of -246.3%. PepGen's return on equity of -- beat Regenxbio's return on equity of -69.62%.

PepGen has a consensus price target of $15.40, signalling upside risk potential of 450%. On the other hand Regenxbio has an analysts' consensus of $36.91 which suggests that it could grow by 431.07%. Given that PepGen has higher upside potential than Regenxbio, analysts believe PepGen is more attractive than Regenxbio.

PepGen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regenxbio has a beta of 1.283, suggesting its more volatile than the S&P 500 by 28.275%.

PepGen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regenxbio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen pays -- of its earnings as a dividend. Regenxbio pays out -- of its earnings as a dividend.

PepGen quarterly revenues are --, which are smaller than Regenxbio quarterly revenues of $24.2M. PepGen's net income of -$21.4M is higher than Regenxbio's net income of -$59.6M. Notably, PepGen's price-to-earnings ratio is -- while Regenxbio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen is -- versus 3.94x for Regenxbio. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -- compared to PepGen's net margin of 7.2%. PepGen's return on equity of -- beat Sarepta Therapeutics's return on equity of 12.48%.

PepGen has a consensus price target of $15.40, signalling upside risk potential of 450%. On the other hand Sarepta Therapeutics has an analysts' consensus of $184.91 which suggests that it could grow by 56.14%. Given that PepGen has higher upside potential than Sarepta Therapeutics, analysts believe PepGen is more attractive than Sarepta Therapeutics.

PepGen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.770, suggesting its less volatile than the S&P 500 by 22.964%.

PepGen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

PepGen quarterly revenues are --, which are smaller than Sarepta Therapeutics quarterly revenues of $467.2M. PepGen's net income of -$21.4M is lower than Sarepta Therapeutics's net income of $33.6M. Notably, PepGen's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 76.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen is -- versus 7.26x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -- compared to PepGen's net margin of 37.71%. PepGen's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -2.89%.

PepGen has a consensus price target of $15.40, signalling upside risk potential of 450%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $489.81 which suggests that it could grow by 18.49%. Given that PepGen has higher upside potential than Vertex Pharmaceuticals, analysts believe PepGen is more attractive than Vertex Pharmaceuticals.

PepGen has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.399, suggesting its less volatile than the S&P 500 by 60.102%.

PepGen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PepGen pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

PepGen quarterly revenues are --, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. PepGen's net income of -$21.4M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, PepGen's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PepGen is -- versus 10.12x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.